Company Filing History:
2 out of 444 
1 out of 8 Years Active: 1980-1990
Title: Miroslav V Bobek: Innovator in Nucleoside Derivatives
Introduction
Miroslav V Bobek is a notable inventor based in Williamsville, NY (US). He has made significant contributions to the field of nucleoside derivatives, particularly in the development of compounds with potential antitumor, antiviral, and antimicrobial properties. With a total of 3 patents, his work has garnered attention in the scientific community.
Latest Patents
Bobek's latest patents include innovative methods for synthesizing 2-substituted arabinopyranosyl nucleosides and nucleotides. These novel arabinopyranosyl nucleoside derivatives feature a heterocyclic moiety and fluorine at the 2' position of the sugar ring, which are prepared through the condensation of a pyrimidine, purine, or 1,3-oxazine base with acylated 2-deoxy-2,2-difluoro-D-arabinopyranoside and/or acylated 2-deoxy-2-bromo-2-fluoro-D-arabinopyranoside. Another significant patent involves the process of preparing 2-azido-2-deoxyarabinofuranosyl halides. This method results in arabinofuranosyl nucleosides and nucleotides that possess 2'-azido, 2'-amino, or 2'-hydrocarbylamino substituents, achieved through a series of chemical reactions that convert the 2'-azido group to a 2'-amino group.
Career Highlights
Throughout his career, Miroslav V Bobek has worked with reputable organizations such as Research Incorporated and Health Research Inc., Roswell Park Division. His expertise in the field has allowed him to contribute to various research projects and advancements in nucleoside chemistry.
Collaborations
Bobek has collaborated with esteemed colleagues, including Alexander Bloch and Yung-Chi Cheng. These partnerships have further enriched his research and development efforts in the field of nucleoside derivatives.
Conclusion
Miroslav V Bobek's innovative work in nucleoside derivatives has the potential to impact the treatment of various diseases. His patents reflect a commitment to advancing scientific knowledge and developing new therapeutic options.